vs
Side-by-side financial comparison of BGSF, INC. (BGSF) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $22.0M, roughly 1.0× BGSF, INC.). BGSF, INC. runs the higher net margin — -5.3% vs -416.2%, a 410.9% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -9.4%). BGSF, INC. produced more free cash flow last quarter ($1.7M vs $-69.4M). Over the past eight quarters, BGSF, INC.'s revenue compounded faster (-5.3% CAGR vs -10.8%).
BGSF Inc. is a leading U.S.-headquartered workforce solutions firm that provides tailored staffing, talent recruitment, and end-to-end workforce management services. It serves core segments including information technology, healthcare, professional administration, light industrial, and creative industries, catering to small, mid-sized and large enterprise clients across North America.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
BGSF vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.0M | $23.0M |
| Net Profit | $-1.2M | $-95.8M |
| Gross Margin | 35.0% | — |
| Operating Margin | -17.6% | -428.9% |
| Net Margin | -5.3% | -416.2% |
| Revenue YoY | -9.4% | 78.8% |
| Net Profit YoY | -18.2% | 25.7% |
| EPS (diluted) | $-0.12 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $22.0M | $23.0M | ||
| Q3 25 | $26.9M | $13.8M | ||
| Q2 25 | $23.5M | $14.2M | ||
| Q1 25 | $20.9M | $16.6M | ||
| Q4 24 | $24.3M | $12.9M | ||
| Q3 24 | $29.8M | $9.1M | ||
| Q2 24 | $25.7M | $7.0M | ||
| Q1 24 | $24.5M | $28.9M |
| Q4 25 | $-1.2M | $-95.8M | ||
| Q3 25 | $-5.8M | $-101.3M | ||
| Q2 25 | $-3.7M | $-101.3M | ||
| Q1 25 | $-722.0K | $-114.3M | ||
| Q4 24 | $-981.0K | $-128.9M | ||
| Q3 24 | $-804.0K | $-135.7M | ||
| Q2 24 | $-761.0K | $-147.0M | ||
| Q1 24 | $-792.0K | $-107.4M |
| Q4 25 | 35.0% | — | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 36.2% | — | ||
| Q4 24 | 35.9% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 37.3% | — | ||
| Q1 24 | 38.1% | — |
| Q4 25 | -17.6% | -428.9% | ||
| Q3 25 | -3.5% | -808.9% | ||
| Q2 25 | -18.8% | -772.2% | ||
| Q1 25 | 1.6% | -726.6% | ||
| Q4 24 | -15.7% | -1059.9% | ||
| Q3 24 | -3.4% | -1589.0% | ||
| Q2 24 | -5.7% | -1998.6% | ||
| Q1 24 | 1.7% | -394.0% |
| Q4 25 | -5.3% | -416.2% | ||
| Q3 25 | -21.6% | -735.2% | ||
| Q2 25 | -15.9% | -710.8% | ||
| Q1 25 | -3.5% | -687.6% | ||
| Q4 24 | -4.0% | -1001.2% | ||
| Q3 24 | -2.7% | -1489.5% | ||
| Q2 24 | -3.0% | -2112.6% | ||
| Q1 24 | -3.2% | -371.3% |
| Q4 25 | $-0.12 | $-0.81 | ||
| Q3 25 | $-0.52 | $-0.92 | ||
| Q2 25 | $-0.34 | $-0.98 | ||
| Q1 25 | $-0.06 | $-1.10 | ||
| Q4 24 | — | $-1.27 | ||
| Q3 24 | $-0.07 | $-1.34 | ||
| Q2 24 | $-0.07 | $-1.52 | ||
| Q1 24 | — | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.1M | $671.4M |
| Total Assets | $57.8M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $449.9M | ||
| Q3 25 | $41.2M | $511.0M | ||
| Q2 25 | $2.8M | $459.7M | ||
| Q1 25 | $2.0M | $503.7M | ||
| Q4 24 | $32.0K | $601.5M | ||
| Q3 24 | $262 | $658.1M | ||
| Q2 24 | $226 | $691.1M | ||
| Q1 24 | $50 | $791.3M |
| Q4 25 | $48.1M | $671.4M | ||
| Q3 25 | $50.7M | $748.4M | ||
| Q2 25 | $78.3M | $715.3M | ||
| Q1 25 | $81.8M | $779.9M | ||
| Q4 24 | $82.3M | $872.0M | ||
| Q3 24 | $82.9M | $962.6M | ||
| Q2 24 | $83.2M | $971.1M | ||
| Q1 24 | $83.6M | $1.0B |
| Q4 25 | $57.8M | $842.1M | ||
| Q3 25 | $83.6M | $925.3M | ||
| Q2 25 | $149.7M | $898.9M | ||
| Q1 25 | $152.3M | $986.2M | ||
| Q4 24 | $150.1M | $1.2B | ||
| Q3 24 | $157.3K | $1.2B | ||
| Q2 24 | $159.8K | $1.2B | ||
| Q1 24 | $170.6K | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7M | $-69.3M |
| Free Cash FlowOCF − Capex | $1.7M | $-69.4M |
| FCF MarginFCF / Revenue | 7.6% | -301.6% |
| Capex IntensityCapex / Revenue | 0.1% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.0K | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $-69.3M | ||
| Q3 25 | $-4.8M | $-76.9M | ||
| Q2 25 | $2.2M | $-99.6M | ||
| Q1 25 | $1.1M | $-148.9M | ||
| Q4 24 | $3.2M | $-85.2M | ||
| Q3 24 | $6.5M | $-84.8M | ||
| Q2 24 | $7.3M | $-58.2M | ||
| Q1 24 | $7.4M | $-120.7M |
| Q4 25 | $1.7M | $-69.4M | ||
| Q3 25 | $-4.9M | $-76.9M | ||
| Q2 25 | $2.1M | $-99.9M | ||
| Q1 25 | $1.0M | $-149.7M | ||
| Q4 24 | $2.5M | $-86.2M | ||
| Q3 24 | $6.5M | $-86.1M | ||
| Q2 24 | $7.3M | $-59.2M | ||
| Q1 24 | $6.9M | $-123.2M |
| Q4 25 | 7.6% | -301.6% | ||
| Q3 25 | -18.1% | -558.2% | ||
| Q2 25 | 9.1% | -701.0% | ||
| Q1 25 | 5.0% | -900.1% | ||
| Q4 24 | 10.2% | -669.4% | ||
| Q3 24 | 21.7% | -945.2% | ||
| Q2 24 | 28.5% | -850.9% | ||
| Q1 24 | 28.1% | -425.7% |
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.4% | 0.2% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.1% | 4.4% | ||
| Q4 24 | 3.0% | 7.6% | ||
| Q3 24 | 0.0% | 14.0% | ||
| Q2 24 | 0.0% | 14.5% | ||
| Q1 24 | 2.0% | 8.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGSF
| Contract Field Talent | $21.4M | 97% |
| Other | $595.0K | 3% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
